NeuroSigma.png
NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
May 09, 2024 09:00 ET | NeuroSigma, Inc.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program. KidsX is a global leader in pediatric digital...
OptimiTM-03.jpg
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
May 09, 2024 08:00 ET | Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
ADCT_4C_TM-R .png
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024 07:15 ET | ADC Therapeutics SA
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
May 09, 2024 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 08, 2024 16:05 ET | Assembly Biosciences, Inc.
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...
Siren Bio Logo with Name.png
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
May 08, 2024 11:00 ET | Siren Biotechnology, Inc.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
JnanaTherapeutics_Logo_FullColor_RGB.png
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 08, 2024 08:00 ET | Jnana Therapeutics, Inc.
Jnana CEO Joanne Kotz will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m. ET.
Cytokinetics.png
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
May 08, 2024 07:30 ET | Cytokinetics, Incorporated
Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a...
Cytokinetics.png
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
May 08, 2024 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce...